Skip to main content
Onxeo logo

Onxeo — Investor Relations & Filings

Ticker · ALONX ISIN · FR0010095596 LEI · 96950018AS30IUG0V528 PA Manufacturing
Open in API
Filings indexed 661 across all filing types
Latest filing 2024-06-05 AGM Information
Country FR France
Listing PA ALONX

About Onxeo

https://www.onxeo.com/

Valerio Therapeutics, formerly Onxeo, is a biotechnology company developing next-generation precision-guided therapies for complex and underserved diseases. The company's core technology is its proprietary V-Body platform, which is based on two fully synthetic single-domain antibody (sdAb) libraries. This platform is engineered to create advanced drug conjugates that enable deep tissue penetration and highly precise therapeutic delivery. By integrating innovative target identification, antibody engineering, and cutting-edge linker and payload technologies, Valerio Therapeutics aims to develop treatments with superior efficacy and target engagement. The company's strategy involves advancing its therapeutic candidates to key development milestones before pursuing strategic partnerships for co-development and out-licensing.

Recent filings

Filing Released Lang Actions
Inside Information / Other news releases
AGM Information Classification · 1% confidence The document explicitly mentions the "Combined General Meeting of June 4, 2024" and reports on the results of the resolutions adopted during this meeting. This directly aligns with the definition of AGM Information (AGM-R), which covers presentations and materials shared during the Annual General Meeting. Although it mentions the minutes will be available later, the core content is the report on the meeting itself.
2024-06-05 English
Inside Information / Other news releases
Regulatory Filings Classification · 1% confidence The document is a press release dated May 22, 2024, providing an update on the clinical development progress of a drug candidate (VIO-01), specifically announcing the completion of dosing for the first cohort in a Phase 1/2 trial and the subsequent clearance by the Clinical Review Committee to escalate to the next dose cohort. This content focuses on operational milestones, safety data, and future trial plans, which is characteristic of an announcement intended to inform investors and the market about recent progress. It is not a full Annual Report (10-K), a formal Audit Report (AR), a detailed Management Discussion & Analysis (MDA), or a formal Earnings Release (ER) which typically focuses on revenue/profit figures. Since it is a specific, timely announcement of clinical progress and operational updates, it best fits the category for general corporate/investor news that doesn't fit the highly specific financial report codes. Given the options, 'Regulatory Filings' (RNS) is the most appropriate fallback for a press release detailing clinical trial updates, as it is a general regulatory disclosure, although 'Investor Presentation' (IP) or 'Earnings Release' (ER) might be considered if the update contained summary financial results, which it does not. Given the focus on clinical milestones, RNS serves as the best general regulatory disclosure category here.
2024-05-22 English
Informations privilégiées / Autres communiqués
Earnings Release Classification · 1% confidence The document is a press release dated May 22, 2024, announcing a clinical development update for the VIO-01 trial (Phase 1/2). It details the completion of the first dose cohort, safety findings (no MTD declared), and the activation of clinical sites. This type of announcement, providing key operational and safety updates on drug development progress, is characteristic of an Earnings Release (ER) if it were tied to a quarterly period, or more generally, a press release announcing significant corporate/pipeline news. Since it is not a full financial report (10-K, IR), a transcript (CT), or a formal regulatory filing like a DVA or DIRS, and it focuses on operational milestones rather than just financial results highlights, it fits best as an Earnings Release (ER) which often includes operational updates, or potentially a Regulatory Filing (RNS) if it were less structured. However, given the structure (headline, bullet points, CEO quote, boilerplate 'About Us', forward-looking statements), it strongly resembles a standard press release used to disseminate key operational news, which often overlaps with the function of an Earnings Release (ER) in the biotech sector, even if it's not strictly quarterly earnings. Since it is a specific update on a clinical trial milestone, and not a general regulatory filing, ER is the most appropriate fit among the provided options for a significant, time-sensitive corporate announcement. FY 2024
2024-05-22 French
Annual financial and audit reports / Terms of availability of the annual financial report
Earnings Release Classification · 1% confidence The document is titled "Valerio Therapeutics Reports Full Year 2023 Financial Results and Provides Clinical Development Updates." It contains detailed consolidated income statements (IFRS) for the years ending 12/31/2023 and 12/31/2022, discusses operating expenses, financial structure as of year-end, and provides a comprehensive review of R&D progress (AsiDNA™, VIO-01). This structure, covering a full fiscal year's performance and detailed financial tables, strongly indicates an Annual Report or a document closely related to it. However, the text explicitly mentions: "The 2023 Financial Report will be available on the Company's website" in the appendix, and the document itself is formatted like a press release summarizing the annual results. Furthermore, the document includes a note: "*Audit procedures on the consolidated accounts have been carried out. The certification report will be issued once the management report has been verified.*" This suggests it is the press release accompanying the release of the full annual financial data, which is typically classified as an Earnings Release (ER) if it focuses on highlights, or potentially an Annual Report (10-K) if it contains the full statutory filing content. Given the comprehensive nature, the inclusion of full IFRS tables, and the discussion of the full fiscal year (FY 2023), it aligns best with the content expected in an Annual Report (10-K) or a very detailed Earnings Release. Since it provides the full financial statements summary and detailed operational review for the entire year, it is more substantial than a typical quarterly earnings release (ER). In the context of US SEC filings, this content is the core of the 10-K. For non-US filers, this detailed annual financial summary is often released as the primary annual document. Given the depth, I classify it as the Annual Report (10-K), as it presents the full year's results and financial position, even if released via a press release format. FY 2023
2024-04-30 English
Rapports financiers et d'audit annuels / Modalités de mise à disposition du rapport financier annuel
Earnings Release Classification · 1% confidence The document is titled "Valerio Therapeutics annonce ses résultats financiers 2023 et fait le point sur son développement clinique" (Valerio Therapeutics announces its 2023 financial results and provides an update on its clinical development). It contains a detailed consolidated income statement (Compte de résultat consolidé) for the years ended 31/12/2023 and 31/12/2022, discusses revenue, operating expenses, net loss, and financial structure as of year-end 2023. It also includes management commentary on financial performance and clinical milestones. This structure is characteristic of a comprehensive annual financial report, although it is presented as a press release announcing the results. Given the depth of the financial tables and the focus on the full fiscal year (2023), it aligns best with the content of an Annual Report (10-K), even if this specific text is the press release version summarizing it. Since the document provides the full year's financial results and detailed operational review, it is classified as an Annual Report (10-K) rather than just an Earnings Release (ER) or a Report Publication Announcement (RPA). FY 2023
2024-04-30 French
Inside Information / Other news releases
Capital/Financing Update Classification · 1% confidence The document explicitly announces a 'reduction of the par value of the Company's shares' and a 'reduction of the share capital by eliminating part of the losses incurred.' This action directly impacts the company's capital structure. Based on the provided definitions, this falls under 'Capital/Financing Update' (Code: CAP), as it details a change in capital structure (reducing nominal value to eliminate losses). Although it involves shares, it is not a standard share issue/buyback (SHA/POS) but a capital restructuring due to losses, making CAP the most appropriate fit. The document length (4450 chars) is substantial enough to be the primary announcement, not just a brief RPA.
2024-02-06 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.